E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
non melanoma skin cancer |
nicht melanozytäre hauttumore |
|
E.1.1.1 | Medical condition in easily understood language |
superficial skin cancer |
oberflächlicher Hautkrebs |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000614 |
E.1.2 | Term | Actinic keratosis |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of photodynamic therapy in combination with 3,75% imioquimod versus photodynamic monotherapy in patients with actinic keratosis |
Der Vergleich der Effektivität einer photodynamischen Therapie versus einer photodynamischen Therapie in Kombination mit 3,75% Imiquimod bei Patienten mit aktinischen Keratosen |
|
E.2.2 | Secondary objectives of the trial |
To compare the tolerability , relapse rate , patients satisfaction and cosmetic results after treatment with photodynamic monotherapy versus photodynamic therapy in combination with 3,75% imiquimod in the patients with actinic keratosis |
Vergleich der Effektivität, Rezidivrate und des kosmetischen Ergenisses einer photodynamischen Monotherapie versus einer photodynamischen Therapie in Kombination mit 3,75% Imiquimod bei Patienten mit aktinischen Keratosen |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with clinically confirmed actinic keratosis in the face and scalp
Age 18 years or older |
Patienten mit aktinischen Keratosen im Gesicht und auf der unbehaarten Kopfhaut
Patienten über 18 Jahren |
|
E.4 | Principal exclusion criteria |
Known allergy to imiquimod and aminlevulinic acid
Patients with porphyria or taking photosensitizing drugs
Patients with severe compromised general state
Patients who are participating in another study
Patients unable to stick to the study protocol
Pregnant or lactating women |
Unverträglichkeit von Imiquimod oder Aminolävilinsäure
Porphyrie oder Einnahme von photosensibilisierenden Medikamenten
Schwere Beeinträchtigung des Allgemeinzustandes
Patienten die an einer anderen Studie teilnehmen
Unvermögen, den Behandlungsplan zu bewältigen bzw. den Pflichten des Studienteilnehmers nachzukommen
Schwangere und stillenede Frauen
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of actinic keratosis cleared 3 months after completion of treatment in both groups |
Prozentsatz von abgeheilten aktinischen Keratosen 3 Monate nach Beendigung der Therapie in beiden Gruppen |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Clinical control after 3 and 6 months after treatment with PDT mono or PDT in combination with imiquimod |
Klinische Kontrolle 3 und 6 Monate nach durchgeführter MonoPDT oder PDT in Kombination mit Imiquimod |
|
E.5.2 | Secondary end point(s) |
The recurrence rate of actinic keratosis at 6 months after completion of therapy in both treatmens groups.
Cosmetic response and global patients satisfaction |
Die Rezidivrate von aktinischen Keratosen 6 Monaten nach Beendigung der Therapie in beiden behandelten Gruppen
Kosmetisches Ergebnis und Patientenzufriedenheit |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Recurrence rate 6 months after completion of therapy in both treatment groups
Cosmetic response and global patients satisfaction 6 moths after completions of therapy in both treatment groups |
Rezidivrate von aktinischen Keratosen 6 Monate nach Beendigung der Therapie in beiden behandelten Gruppen.
Kosmetische Beurteilung sowie globale Patientenzufriedenheit 6 Monaten nach Beendigung der Therapie in beiden Gruppen |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
observer-blinded, gepaart, monozentrisch |
observer-blind, paired, monocentric |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
end of the trial after completion of the follow up examinations 6 months after the therapy in 56 participants |
Das Ende der Studie ist nach der abgeschlossenen klinischen Kontrollen 6 Monate nach Beendigung der Therapie bei 56 Patienten |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | 0 |